Viridian Therapeutics, Inc.

VRDN· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$25.30+2.55%

2026-11-02

Financials

Valuation Metrics

Viridian Therapeutics, Inc.'s Market Cap is $2.87B. At end of 2025 it was $2.64B. Ranked #1747 of 3,118 in US market (top 56%), #624 of 1,474 on NASDAQ (top 42%), #108 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$2.87B	US#1,747/3,118 Sec#108/265
Revenue	$71M	US#2,715/3,118 Sec#135/265
Net Income	$-387M	US—/3,118 Sec—/265
Total Assets	$1.10B	US#2,421/3,118 Sec#96/265
Net Assets	$662M	US#2,044/3,118 Sec#89/265
Value
P/B	4.33x	US#2,094/3,118 Sec#134/265
P/S	40.30x	US#2,907/3,118 Sec#163/265
FCF Yield	-11.69%	US—/3,118 Sec—/265
Profitability
ROE	-58.45%	US#2,707/3,118 Sec#171/265
ROA	-35.27%	US#2,915/3,118 Sec#176/265
Op. Margin	-569.68%	US#2,783/3,118 Sec#155/265
Revenue Growth	23220.33%	US#4/3,118 Sec#2/265
Financial Health
Debt Ratio	65.72%	US#721/3,118 Sec#145/265
Total Debt	$243M	US#2,173/3,118 Sec#92/265
FCF	$-335M	US#2,858/3,118 Sec#238/265
Cash	$165M	US#1,877/3,118 Sec#125/265
Current Ratio	16.95x	US#140/3,118 Sec#36/265
Performance
1Y Return	7.07%	US#1,684/3,118 Sec#140/265
1M Return	30.41%	US#236/3,118 Sec#18/265
From 52W High	-26.22%	US#1,858/3,118 Sec#110/265
1Y MDD	-60.63%	US#2,731/3,118 Sec#204/265
Trading
Volume	3,262,095 shares	US#1,187/3,118 Sec#114/265
Trading Value	$81M	US#1,513/3,118 Sec#105/265
Per Share
EPS	$-3.42	US—/3,118 Sec—/265
BPS	$5.84	US#2,206/3,118 Sec#115/265